116 related articles for article (PubMed ID: 11810558)
21. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
22. Comparative grepafloxacin phototoxicity in mouse skin.
Owen K
J Antimicrob Chemother; 1998 Aug; 42(2):261-4. PubMed ID: 9738848
[TBL] [Abstract][Full Text] [Related]
23. Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
Shakibaei M; Baumann-Wilschke I; Rücker M; Stahlmann R
Arch Toxicol; 2002 Jan; 75(11-12):725-33. PubMed ID: 11876506
[TBL] [Abstract][Full Text] [Related]
24. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
Van de Velde S; Nguyen HA; Van Bambeke F; Tulkens PM; Grellet J; Dubois V; Quentin C; Saux MC
J Antimicrob Chemother; 2008 Sep; 62(3):518-21. PubMed ID: 18544595
[TBL] [Abstract][Full Text] [Related]
25. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
Lode H; Vogel F; Elies W
Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
[TBL] [Abstract][Full Text] [Related]
26. Grepafloxacin.
Wagstaff AJ; Balfour JA
Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
[TBL] [Abstract][Full Text] [Related]
27. Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats.
Suzuki T; Kato Y; Sasabe H; Itose M; Miyamoto G; Sugiyama Y
Drug Metab Dispos; 2002 Dec; 30(12):1393-9. PubMed ID: 12433809
[TBL] [Abstract][Full Text] [Related]
28. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Yamaguchi H; Yano I; Hashimoto Y; Inui KI
J Pharmacol Exp Ther; 2000 Oct; 295(1):360-6. PubMed ID: 10992002
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats.
Takizawa T; Hasimoto K; Itoh N; Yamashita S; Owen K
Hum Exp Toxicol; 1999 Jan; 18(1):38-45. PubMed ID: 10025367
[TBL] [Abstract][Full Text] [Related]
30. Differential uptake of grepafloxacin by human circulating blood neutrophils and those exudated into tissues.
Niwa M; Hotta K; Kanamori Y; Matsuno H; Kozawa O; Hirota M; Uematsu T
Eur J Pharmacol; 2001 Sep; 428(1):121-6. PubMed ID: 11779028
[TBL] [Abstract][Full Text] [Related]
31. In-vitro anti-inflammatory and immunomodulatory effects of grepafloxacin in zymogen A- or Staphylococcus aureus-stimulated human THP-1 monocytes.
Ives TJ; Schwab UE; Ward ES; Hall IH
J Infect Chemother; 2003 Jun; 9(2):134-43. PubMed ID: 12825112
[TBL] [Abstract][Full Text] [Related]
32. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
Ito T; Yano I; Masuda S; Hashimoto Y; Inui K
Pharm Res; 1999 Apr; 16(4):534-9. PubMed ID: 10227708
[TBL] [Abstract][Full Text] [Related]
33. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
Tamai I; Yamashita J; Kido Y; Ohnari A; Sai Y; Shima Y; Naruhashi K; Koizumi S; Tsuji A
J Pharmacol Exp Ther; 2000 Oct; 295(1):146-52. PubMed ID: 10991972
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of possible metabolites of 1-cyclopropyl-1,4-dihydro-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)- 4-oxo-3-quinolinecarboxylic acid (Grepafloxacin, OPC-17116).
Morita S; Otsubo K; Matsubara J; Ohtani T; Kawano Y; Ohmori K; Ohguro K; Uchida M
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2246-52. PubMed ID: 8582026
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of fluoroquinolone transport by human neutrophils.
Walters JD; Zhang F; Nakkula RJ
Antimicrob Agents Chemother; 1999 Nov; 43(11):2710-5. PubMed ID: 10543751
[TBL] [Abstract][Full Text] [Related]
36. New fluoroquinolone antibiotics.
Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769
[TBL] [Abstract][Full Text] [Related]
37. Safety of the new fluoroquinolones compared with ciprofloxacin.
Ball P
J Chemother; 2000 Jan; 12 Suppl 1():8-11. PubMed ID: 11414383
[TBL] [Abstract][Full Text] [Related]
38. Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism.
Niwa M; Kanamori Y; Hotta K; Matsuno H; Kozawa O; Fujimoto S; Uematsu T
J Antimicrob Chemother; 2002 Oct; 50(4):469-78. PubMed ID: 12356790
[TBL] [Abstract][Full Text] [Related]
39. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.
Michot JM; Seral C; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
Antimicrob Agents Chemother; 2005 Jun; 49(6):2429-37. PubMed ID: 15917543
[TBL] [Abstract][Full Text] [Related]
40. Disposition and intracellular levels of moxifloxacin in human THP-1 monocytes in unstimulated and stimulated conditions.
Hall IH; Schwab UE; Ward ES; Ives T
Int J Antimicrob Agents; 2003 Dec; 22(6):579-87. PubMed ID: 14659655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
